- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07945470
Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma (SIMPLY)
SIMulation-free Protocols for Lymphoma RadiotherapY [SIMPLY]
This pilot study will evaluate whether people with indolent B-cell lymphoma can receive radiation therapy without a separate computed tomography (CT) simulation appointment. Participants will receive one low-dose radiation treatment of 4 gray (Gy). Treatment planning will use a recent diagnostic CT scan, and cone-beam computed tomography (CBCT) imaging on the treatment day will be used to confirm participant positioning and adjust the treatment plan if needed.
The study includes participants with orbital or ocular adnexal lymphoma and participants with lymphoma at other body sites. The investigators will assess whether simulation-free treatment can be completed successfully, treatment duration, the number of hospital visits required, treatment side effects, patient-reported symptoms, control of the treated lymphoma site, and the need for additional treatment. Participants will be followed for up to 12 months.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This prospective, single-centre, single-arm pilot feasibility study evaluates a simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy workflow for participants with indolent B-cell lymphoma.
Participants will receive single-fraction ultra-low-dose radiation therapy consisting of 4 Gy delivered in one treatment session. Instead of undergoing a separate CT simulation, treatment planning will use a recent diagnostic CT scan suitable for contouring and dose calculation.
On the treatment day, CBCT imaging will be obtained to confirm participant positioning and anatomy. The treatment plan may be adapted while the participant is on the treatment couch and will be reviewed and approved before radiation delivery.
The study includes two cohorts:
Participants with orbital or ocular adnexal indolent B-cell lymphoma.
Participants with non-orbital indolent B-cell lymphoma.
If an acceptable simulation-free treatment plan cannot be produced, the participant will proceed through the standard CT simulation-based treatment process. This will be recorded as an unsuccessful simulation-free workflow but will not prevent the participant from receiving clinically appropriate treatment.
The primary objective is to determine the proportion of participants who successfully complete treatment without requiring conventional CT simulation.
Secondary assessments include treatment timing, on-couch time, hospital visits avoided, reasons for workflow failure, treatment-related side effects, patient-reported symptoms, local control of the treated site at 6 months, and retreatment of the treated site within 12 months.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Mahmood AminiLari, PhD
- Numero di telefono: 6522 4169464501
- Email: mahmood.aminilari@uhn.ca
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X6
- Reclutamento
- Princess Margaret Cancer Centre, University Health Network
-
Contatto:
- Mahmood AminiLari, PhD
- Numero di telefono: 6522 4169464501
- Email: mahmood.aminilari@uhn.ca
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically confirmed indolent B-cell lymphoma, including marginal zone/mucosa-associated lymphoid tissue (MALT) lymphoma, follicular lymphoma grades 1-2, small lymphocytic lymphoma, or mantle cell lymphoma.
- Disease requiring focal radiation therapy with 4 Gy delivered in one fraction for local control or symptom relief.
- Lesion anatomy suitable for single-fraction radiation therapy and simulation-free, CBCT-guided treatment delivery, as determined by the treating radiation oncologist.
- Available diagnostic CT imaging suitable for contouring and dose calculation that encompasses the full intended target and relevant organs at risk:
- Obtained within 2 months before treatment for orbital or ocular adnexal disease.
- Obtained within 6 weeks before treatment for non-orbital disease.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, with the ability to tolerate treatment positioning and delivery.
- Localized or advanced-stage disease is permitted, provided the target lesion is appropriate for focal treatment.
Exclusion Criteria:
- Diagnostic imaging that does not meet the minimum quality requirements for treatment planning or falls outside the required time window.
- Disease anatomy unsuitable for simulation-free delivery, such as inability to maintain stable positioning, excessive motion, or inadequate CBCT visualization.
- Prior radiation therapy to the same site if re-irradiation using the study workflow is considered clinically inappropriate.
- Bulky disease greater than 6 centimeters for which single-fraction 4 Gy radiation therapy is unlikely to provide adequate local control, as determined by the treating physician.
- Requirement for urgent systemic therapy because of widespread or symptomatic disease.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Simulation-Free Single-Fraction Radiation Therapy
Participants will receive simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy delivered as a single 4 gray (Gy) fraction. Treatment planning will use a recent diagnostic computed tomography (CT) scan instead of a separate planning CT simulation. CBCT imaging will be obtained on the treatment day to confirm positioning and anatomy and to adapt the treatment plan when needed. Participants for whom the simulation-free workflow is not feasible will proceed to standard CT simulation-based treatment. |
Participants will receive a single 4 gray (Gy) fraction of radiation therapy using a simulation-free workflow. A recent diagnostic computed tomography (CT) scan suitable for contouring and dose calculation will be used for initial treatment planning instead of a separate planning CT simulation. On the treatment day, cone-beam computed tomography (CBCT) imaging will be obtained to confirm positioning and anatomy. The treatment plan may be adapted on the treatment couch and will undergo physician and physics review before radiation is delivered. If a clinically acceptable simulation-free plan cannot be produced, the participant will proceed to the standard CT simulation-based workflow.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Successful Completion of Simulation-Free Radiation Therapy
Lasso di tempo: Periprocedural (single radiation treatment session)
|
Proportion of participants who successfully complete the prescribed single-fraction 4 Gy radiation treatment using the simulation-free, cone-beam CT-guided adaptive workflow without requiring fallback to conventional CT simulation. The workflow will be considered feasible if at least 80% of participants complete treatment without conventional CT simulation. |
Periprocedural (single radiation treatment session)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time From Radiation Oncology Consultation to Treatment
Lasso di tempo: From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks
|
Number of calendar days between the radiation oncology consultation date and the date of radiation treatment. |
From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks
|
|
Same-Day Treatment
Lasso di tempo: Day 1 (date of radiation oncology consultation)
|
Proportion of participants who receive radiation treatment on the same calendar day as their radiation oncology consultation. |
Day 1 (date of radiation oncology consultation)
|
|
Total On-Couch Time
Lasso di tempo: Periprocedural (single radiation treatment session)
|
Total number of minutes the participant spends on the treatment couch, measured from initial positioning to completion of radiation delivery. |
Periprocedural (single radiation treatment session)
|
|
Number of Hospital Visits
Lasso di tempo: From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks
|
Number of hospital visits occurring between referral to Radiation Oncology and completion of radiation treatment. The observed number will be used to estimate visits avoided compared with the conventional CT simulation-based workflow. |
From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks
|
|
CT Simulation Avoided
Lasso di tempo: Periprocedural (through completion of the single radiation treatment session)
|
Proportion of participants who complete radiation treatment without requiring a separate conventional CT simulation appointment. |
Periprocedural (through completion of the single radiation treatment session)
|
|
Reasons for Simulation-Free Workflow Failure
Lasso di tempo: From treatment planning through radiation treatment completion, up to 4 weeks
|
Reasons that the simulation-free workflow could not be completed, including inadequate diagnostic imaging, changes in anatomy, positioning difficulties, inadequate cone-beam CT visualization, or inability to produce an acceptable treatment plan. |
From treatment planning through radiation treatment completion, up to 4 weeks
|
|
Clinician-Graded Treatment-Related Toxicity
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment
|
Incidence and severity of treatment-related adverse events assessed using the Common Terminology Criteria for Adverse Events, version 5.0. The proportions of participants experiencing Grade 2 or higher and Grade 3 or higher events will be reported. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Ocular Surface Disease Index Score
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment
|
Change in Ocular Surface Disease Index score among participants with orbital or ocular adnexal lymphoma. Higher scores indicate greater ocular-surface-related symptoms and functional impairment. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Head and Neck Quality-of-Life Symptoms
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment
|
Change in relevant patient-reported symptoms measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 43 among applicable participants with head-and-neck treatment sites. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Index Symptom Severity
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment
|
Change in the participant's main treatment-related symptom measured using a numeric rating scale from 0 to 10, where 0 indicates no symptom and 10 indicates the worst imaginable symptom. |
Baseline, 2-4 weeks, and 3 months after treatment
|
|
Local Control of the Treated Site
Lasso di tempo: 6 months after radiation treatment
|
Proportion of participants without radiographic or clinical progression within the irradiated site. Local control will be determined using the best routinely available assessment modality, which may include PET/CT, CT, MRI, ophthalmologic assessment, or clinical examination. |
6 months after radiation treatment
|
|
Retreatment of the Treated Site
Lasso di tempo: Within 12 months after radiation treatment
|
Proportion of participants who require additional local or systemic treatment for inadequate response or progression at the irradiated site. |
Within 12 months after radiation treatment
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Neoplasie
- Malattia cronica
- Attributi della malattia
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Leucemia, cellule B
- Linfoma, cellule B
- Linfoma
- Leucemia, linfoide
- Leucemia
- Condizioni patologiche, segni e sintomi
- Malattie emiche e linfatiche
- Leucemia, linfocitica, cronica, cellule B
- Linfoma, follicolare
- Linfoma, cellule del mantello
- Linfoma, cellula B, zona marginale
Altri numeri di identificazione dello studio
- 26-5319
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .